Vitamin C linked to improved outcomes in people with precancerous blood disorders
· Medical Xpressby Wiley
edited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off. Because decreased function of TET enzymes is a common driver of certain forms of blood cancer, researchers tested the effects of vitamin C supplements in patients at risk of developing such malignancies.
Results of the investigators' Phase II clinical trial are published in Cancer.
The randomized, double-blind, placebo-controlled EVITA trial enrolled 109 patients in Denmark and the United States who had either a blood condition that can turn cancerous or a low-risk form of blood cancer. At the start of the trial, 55 patients were randomly assigned to receive oral vitamin C (1,000 mg/day) and 54 were assigned to receive placebo for a total of 12 months.
Although the primary endpoint—growth rate of precancerous or cancerous cells—was similar between groups, participants who received vitamin C experienced changes in inflammatory signaling that align with better outcomes. Also, anemia, pneumonia, acute aseptic arthritis and internal bleeding were less frequent (although gastrointestinal problems were more frequent) in patients taking vitamin C compared with those taking placebo.
At a median follow-up of 33.6 months (nearly three years) in the intention-to-treat population, 35 deaths were recorded, including 24 in the placebo group and 11 in the vitamin C group. An exploratory analysis of these data found that participants in the vitamin C group were more likely to survive during follow-up than those in the placebo group. This finding requires confirmation in a larger Phase III trial.
"The EVITA trial gives us a strong rationale to continue exploring whether and how vitamin C might benefit people with certain precancerous or early-stage blood cancers. More work is needed, but we are cautiously optimistic that these findings could inform future strategies to intercept leukemia development," said co-senior author Peter A. Jones, Ph.D., DSc (hon), of Van Andel Institute in Grand Rapids, Michigan. Jones is co-leader of the Van Andel Institute–Stand Up To Cancer (VAI–SU2C) Epigenetics Dream Team, which led the EVITA trial.
"We are encouraged by our findings and what they ultimately could mean for people with these early-stage blood disorders. Although it is too soon to make recommendations based on our results, we are hopeful that a larger study will give us more definitive answers," added co-senior author Kirsten Grønbæk, MD, Ph.D., of Rigshospitalet, Copenhagen University Hospital in Denmark. Grønbæk is a longtime member of the VAI–SU2C Epigenetics Dream Team.
Publication details
Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized placebo-controlled trial, Cancer (2026). DOI: 10.1002/cncr.70549
Journal information: Cancer
Key medical concepts
Clinical categories
OncologyClinical pharmacology Provided by Wiley Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Vitamin C linked to improved outcomes in people with precancerous blood disorders (2026, September 21) retrieved 21 September 2026 from https://medicalxpress.com/news/2026-09-vitamin-linked-outcomes-people-precancerous.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.